4.7 Article

Early and late recurrence patterns of pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: a multicenter study

Related references

Note: Only part of the references are listed.
Article Oncology

Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis

Yoshihiko Tomita et al.

Summary: The study showed that avelumab as first-line maintenance therapy significantly prolonged overall survival and progression-free survival in Japanese patients with advanced urothelial carcinoma. The efficacy and safety results were consistent with the overall trial population, supporting avelumab as a new standard of care in Japanese patients with advanced UC that has not progressed with first-line platinum-containing chemotherapy.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Oncology

Pan-cancer analysis of prognostic metastatic phenotypes

Nicholas G. Zaorsky et al.

Summary: This project aimed to redefine staging of metastatic cancer, identified five metastatic phenotypes through latent class analysis, and found long-term survivors. All metastatic cancer is considered as Stage IV disease.

INTERNATIONAL JOURNAL OF CANCER (2022)

Article Surgery

Practice Patterns and Perioperative Outcomes of Laparoscopic Pancreaticoduodenectomy in China A Retrospective Multicenter Analysis of 1029 Patients

Min Wang et al.

Summary: The study on LPD outcomes in China demonstrates that the procedure is technically safe and feasible with acceptable rates of morbidity and mortality. Factors such as surgical experience, hospital and surgeon volume are associated with surgical failure risks.

ANNALS OF SURGERY (2021)

Article Surgery

Learning Curve From 450 Cases of Robot-Assisted Pancreaticoduocectomy in a High-Volume Pancreatic Center Optimization of Operative Procedure and a Retrospective Study

Yusheng Shi et al.

Summary: This study retrospectively analyzed 450 cases of robot-assisted pancreaticoduodenectomy to describe the experience and learning curve, with improvements in operative time and estimated blood loss observed over time. The inflexion points in the RPD learning curve were identified around cases 100 and 250, and a significantly lower incidence of pancreatic leak was found in the last 350 cases compared to the first 100 cases.

ANNALS OF SURGERY (2021)

Article Surgery

Recurrence patterns and postrecurrence survival after curative intent resection for pancreatic ductal adenocarcinoma

Hordur Kolbeinsson et al.

Summary: Pancreatic ductal adenocarcinoma has a high rate of recurrence after resection, with liver metastasis being the most common distant site of recurrence. Patients with poorly differentiated tumors are more likely to recur in the liver. Liver-directed therapies should be a focus for future studies.

SURGERY (2021)

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Article Surgery

STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery

Ginimol Mathew et al.

Summary: The updated STROCSS 2021 guidelines, developed through a consensus exercise by an expert panel, received high levels of agreement from the participants, ensuring ongoing good reporting quality in observational studies in surgery.

INTERNATIONAL JOURNAL OF SURGERY (2021)

Article Cell Biology

Development and validation of glycolysis-related prognostic score for prediction of prognosis and chemosensitivity of pancreatic ductal adenocarcinoma

Xiu-Ping Zhang et al.

Summary: This study developed a glycolysis-related prognosis (GRP) score based on 29 glycolysis prognostic genes for predicting prognosis and chemosensitivity in pancreatic ductal adenocarcinoma (PDAC) patients. The score was validated in multiple cohorts and found to be closely related to specific metabolism pathways, immune genes, and immune cells in PDAC patients. Additionally, the GRP score combined with immune cells demonstrated good predictive ability for chemosensitivity in PDAC patients.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2021)

Article Medicine, General & Internal

Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression

Kai Chen et al.

Summary: This study utilized single-cell RNA sequencing to explore the dynamic changes of tumor microenvironment components during PDAC malignant progression, revealing gradual accumulation of immune cells and pancreatic stellate cells. New Treg and exhausted T cell signature genes were identified, and patients with high expression of certain genes had significantly worse prognosis. A new subset of CAFs specific to PDAC, csCAFs, was also discovered.

EBIOMEDICINE (2021)

Article Oncology

Perioperative Predictors of Early Recurrence for Resectable and Borderline-Resectable Pancreatic Cancer

Masafumi Imamura et al.

Summary: Most patients with pancreatic ductal adenocarcinoma experience a recurrence after surgery, with preoperative and postoperative elevated CA19-9 levels, as well as a tumor size >3.0 cm, independently predicting early recurrence. Early recurrence is associated with more frequent liver metastasis, suggesting the presence of undetected micrometastases. New biomarkers are needed to accurately identify patients at risk for early recurrence.

CANCERS (2021)

Article Oncology

Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial

Xiaofei Zhu et al.

Summary: This study aimed to evaluate the efficacy of SBRT plus pembrolizumab and trametinib in patients with postoperative locally recurrent pancreatic cancer. Among 198 patients, the median overall survival was significantly longer in the SBRT plus pembrolizumab and trametinib group compared to the SBRT plus gemcitabine group. The most common adverse effects were mild to moderate in severity.

LANCET ONCOLOGY (2021)

Article Cell Biology

Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response

Yu Wang et al.

Summary: The study investigated the heterogeneity among PDAC patients in terms of CAFs, ductal cancer cells, and immune cells, revealing differences between dense-type and loose-type PDAC. A novel subtype of CAFs, meCAFs, was discovered in loose-type PDAC, playing a critical role in disease progression and response to immunotherapy. This finding highlights the importance of considering intertumoral heterogeneity in PDAC treatment strategies.

CELL DISCOVERY (2021)

Article Oncology

Clinical Effects of Stereotactic Body Radiation Therapy Targeting the Primary Tumor of Liver-Only Oligometastatic Pancreatic Cancer

Xiaoqin Ji et al.

Summary: The addition of SBRT to chemotherapy has shown to improve overall survival in liver-only oligometastatic pancreatic cancer patients, especially those with primary tumor located in the head of pancreas or good performance status. Moreover, SBRT is a safe and effective method for local progression control and local symptomatic relief in patients with metastatic pancreatic cancer.

FRONTIERS IN ONCOLOGY (2021)

Article Gastroenterology & Hepatology

A Therapeutic Strategy for Resectable Pancreatic Cancer Based on Risk Factors of Early Recurrence

Hiroshi Kurahara et al.

PANCREAS (2018)

Article Oncology

Preoperative predictors for early recurrence of resectable pancreatic cancer

Kohei Nishio et al.

WORLD JOURNAL OF SURGICAL ONCOLOGY (2017)

Review Medicine, General & Internal

Pancreatic cancer

Terumi Kamisawa et al.

LANCET (2016)

Article Medicine, General & Internal

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Article Oncology

Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma

Matthew H. G. Katz et al.

ANNALS OF SURGICAL ONCOLOGY (2009)

Article Surgery

One thousand consecutive pancreaticoduodenectomies

JL Cameron et al.

ANNALS OF SURGERY (2006)

Article Medicine, General & Internal

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

JP Neoptolemos et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)